A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

A single treatment with, a CRISPR-Cas9-based gene editing therapy, is enough to replace the daily medication of patients with ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regularly ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $20.0 for Intellia Therapeutics over the recent three months.

According to a new comprehensive report from The Insight Partners, the Global Organoid Market is witnessing significant ...

Poseida Therapeutics, Inc. , a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated ...

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...